# HBsAg Related Response Guided Therapy

> **NCT01456312** · PHASE4 · UNKNOWN · sponsor: **Gangnam Severance Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT01456312
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2016-02
- **Final completion:** 2016-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2012-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456312, "HBsAg Related Response Guided Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01456312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*